Clinical Study
The Routine Use of Prophylactic Oxytocin in the Third Stage of Labor to Reduce Maternal Blood Loss
Table 1
The maternal characteristics and perinatal outcomes in each group.
| | | Control group
() | RUPO group
() | value |
| | Maternal age (years) | | | NS | | Nulliparous (%) | 221 (54.3%) | 196 (50.0%) | NS | | Prepregnancy BMI (kg/m2) | | | NS | | Prepregnancy obesity (BMI ≥ 25) | 41 (10.1%) | 61 (15.5%) | | | Leiomyomas (%) | 10 (2.5%) | 12 (3.1%) | NS | | Preeclampsia (%) | 11 (2.7%) | 8 (2.0%) | NS | | Hydramnios (%) | 14 (3.4%) | 10 (2.5%) | NS | | Gestational age at delivery (weeks) | | | NS | | Birthweight (g) | 2,895 ± 619 | 2,871 ± 561 | NS | | Macrosomia ≥ 4,000 g (%) | 6 (1.5%) | 3 (0.8%) | NS | | Induction of labor with oxytocin (%) | 106 (26%) | 107 (27%) | NS | | Duration of labor (min) | | | NS | | Prolonged labor (%) | 12 (2.9%) | 33 (8.4%) | | | Duration of the second stage of labor (min) | | | NS | | Prolonged second stage of labor (%) | 73 (17.9%) | 70 (17.8%) | NS | | Vacuum extraction (%) | 20 (4.9%) | 20 (5.1%) | NS | | Cervical laceration (%) | 3 (0.7%) | 0 (0%) | NS |
|
|
RUPO, routine use of prophylactic oxytocin; BMI, body mass index.
|
